Supplementary Information
cancer, Dukes’ B3 or C, colon cancer, Dukes’ B2 colon cancer
CANCER, COLON CANCER, MAY, SECONDARY, ONCOLOGY
The online version contains supplementary material available at 10.1245/s10434-022-12705-8.The optimal timing of adjuvant chemotherapy after curative colon cancer surgery is unknown, but modeling of cancer dynamics implicates it as an important determinant of the therapeutic outcome.With these considerations in mind, the Eastern Cooperative Oncology Group (ECOG, now ECOG-ACRIN) together with the NCI Intergroup conducted a prospective randomized trial designed to test whether chemotherapy started within 24 h of surgery would be safe and more effective than standard adjuvant chemotherapy 3–6 weeks or longer after surgery. This report is the final analysis of this multi-institutional, prospective randomized trial, 15 years after the trial termination in May 2000, to study the effects of perioperative chemotherapy. The primary objective was to determine whether 1 week of infusional 5-fluorouracil (5-FU) started within 24 h of curative colon resection followed by standard 5-FU-based adjuvant chemotherapy is effective in increasing overall survival (OS) in patients with Dukes’ B3 or C (AJCC stages IIC or III) colon cancer compared with standard adjuvant chemotherapy alone. A secondary objective was to describe the treatment effect of perioperative 5-FU in patients with Dukes’ B2 colon cancer compared with no chemotherapy.